We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Noninvasive Ventilation and Outcomes Among Immunocompromised Patients—Reply

Virginie Lemiale, MD1; Djamel Mokart, MD2; Elie Azoulay, MD, PhD1 ; Groupe de Recherche en Réanimation Respiratoire Onco-Hématologique (GRRR-OH)
[+] Author Affiliations
1Saint-Louis University Hospital, Paris, France
2IPC, Lyon, France
JAMA. 2016;315(17):1902-1903. doi:10.1001/jama.2016.0692.
Text Size: A A A
Published online


In Reply As suggested by Dr Frat and colleagues, we cannot rule out that high-flow oxygen undermined the effect of noninvasive ventilation on outcomes. Use of high-flow oxygen may be one advance that accounts for reduced mortality in immunocompromised patients with acute respiratory failure. We agree that before drawing any conclusions, the strengths and weaknesses of high-flow oxygen still need to be appraised in trials dedicated to this specific purpose. In our trial, high-flow oxygen was used in 37% of patients, with no differences in crude mortality rates between patients receiving or not receiving high-flow oxygen (41/141 vs 55/233, P = .24).


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




May 3, 2016
Jean-Pierre Frat, MD; Rémi Coudroy, MD; Arnaud W. Thille, MD, PhD
1CHU de Poitiers, Medical Intensive Care Unit, Poitiers, France
JAMA. 2016;315(17):1901-1902. doi:10.1001/jama.2016.0674.
May 3, 2016
Paolo Navalesi, MD; Cesare Gregoretti, MD; Massimo Antonelli, MD
1Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy
2Department of Biopathology and Medical Biotechnologies, University of Palermo, Palermo, Italy
3Department of Anesthesiology and Intensive Care Medicine, Università Cattolica del Sacro Cuore, Rome, Italy
JAMA. 2016;315(17):1902. doi:10.1001/jama.2016.0677.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...